Many questions surrounding Medical Remanufacturing deserve to be considered objectively and in their proper context. We have therefore summarised our position on the regulated reprocessing of single-use medical devices in this statement. It addresses the regulatory, procedural and quality requirements that are essential for the use of regulated reprocessed medical devices and considers how these requirements can be implemented transparently and verifiably in practice.
Statement on the Regulated Reprocessing of Single-Use Medical Devices
The reprocessing of single-use medical devices is becoming an increasingly important topic for hospitals, operating theatre teams and procurement departments. This is a positive development. After all, any serious discussion about security of supply, cost-effectiveness and sustainability in healthcare must also consider validated circular economy models.
At the same time, one thing is becoming apparent: the more relevant Medical Remanufacturing becomes, the more frequently broad concerns are raised. These may relate to allegedly unclear responsibilities, potential variations in performance, operational risks, hidden costs or reputational issues. At first glance, these concerns may sound significant. What matters, however, is whether they are supported by evidence.
A claim is not evidence simply because it has been made.
Medical Remanufacturing is neither an experiment nor an unregulated activity. It is subject to clearly defined regulatory requirements. In the EU, the Medical Device Regulation (MDR) provides the legal framework. The requirements of Article 17 of the MDR apply. Depending on the reprocessing model, either all manufacturer obligations under the MDR must be fulfilled, or the manufacturer obligations under the MDR apply together with the requirements of the Common Specifications referred to in Article 17. These include, among other things, risk management, process validation, quality management, product release, performance testing, documentation, traceability and incident reporting.
In the United Kingdom, Medical Remanufacturing is carried out in accordance with the UK Guidance 2016, as amended from time to time. The "Re-Manufacturer" must comply with all requirements of the relevant medical devices legislation. In accordance with the UK Guidance 2016, before being placed on the market or put into service, the medical device must be cleaned, disinfected and sterilised and tested against the Re-Manufacturer's specifications to ensure that the single-use device continues to be safe and performs as intended.
Following Medical Remanufacturing, the single-use medical device must once again bear the applicable conformity marking, either the CE marking or the UKCA marking, for which the Re-Manufacturer is responsible. For all medical devices intended to be used in a sterile condition, this requires conformity certification by a Notified Body or a UK Approved Body, as applicable.
This is precisely why it is worth examining more closely the points that are repeatedly raised in discussions about Medical Remanufacturing.
Responsibility and Traceability
The claim that responsibility could become unclear in the event of an incident involving a regulated reprocessed single-use medical device does not reflect the regulatory framework. In fact, responsibility is clearly defined by regulation.
The applicable regulatory requirements, whether under the MDR or UK Guidance, expressly set out the conditions under which single-use devices may be reprocessed and reused. Where reprocessing is carried out under the CE framework, the reprocessor assumes the corresponding manufacturer obligations. Where reprocessing is carried out for healthcare institutions in accordance with Article 17(3) to (5) MDR, the Common Specifications apply, setting out clear requirements for documentation, traceability, product release and reporting procedures.
Responsibility is therefore not blurred. It is structured, documented and made verifiable.
Reliability and Consistent Quality
The general assumption that regulated reprocessed medical devices are less reliable or less consistent than original single-use devices is not, in itself, a substantiated professional assessment.
The decisive factor is not whether a product was originally placed on the market as a single-use device, but whether its reprocessing is validated, quality-assured and permitted under the applicable regulatory framework.
Medical Remanufacturing is based on certified cleaning, disinfection, testing and sterilisation processes. These are complemented by performance and functional testing as well as final product release. A device is only returned to use if it meets all defined requirements.
Operating Theatre Procedures and Team Support
Operating theatre teams need products they can rely on. This is precisely why regulated reprocessing is not merely a technical procedure, but a comprehensive, quality-assured process.
It includes defined acceptance criteria, validated reprocessing steps, documented testing and clear release criteria. Regulated reprocessed medical devices are designed to be safely integrated into existing clinical workflows and used for their intended purpose.
Any suggestion that potential disruptions in the operating theatre are inherently linked to reprocessing should be supported by specific evidence. Hypothetical uncertainty is no substitute for a fact-based assessment.
Cost-Effectiveness Beyond the Unit Price
It is right to assess Medical Remanufacturing on more than unit price alone. This is precisely the approach taken by Vanguard.
What matters is the overall assessment of quality, availability, process reliability, resource use, waste prevention and economic benefit. However, anyone suggesting that savings are routinely offset by alleged variations in performance, additional product consumption or increased staffing requirements should provide evidence to support that claim.
Regulated reprocessing is not simply a cost-saving model. It combines economic benefits with quality-assured processes and a more responsible use of resources.
Patient Transparency and Communication
Transparency towards patients is important. However, transparency should not be equated with raising unsubstantiated concerns.
Regulated reprocessed medical devices are not second-class products. They may only be reused if the applicable regulatory requirements have been met.
Clear and objective communication can explain that Medical Remanufacturing is based on regulatory requirements, validated processes and documented quality assurance. Particularly in a private healthcare setting, transparent, understandable and fact-based communication is essential.
It is not the use of regulated reprocessed products that requires justification, but rather any blanket dismissal of such products without supporting evidence.
Reputation and Hospital Responsibility
The use of validated circular economy models can send a strong signal of responsible hospital management. Hospitals today face the challenge of combining high standards of care with economic pressures, resource constraints and sustainability objectives.
Regulated reprocessing provides a legally recognised and quality-assured approach to addressing these challenges. Reputational risks do not arise simply because hospitals use validated, safe and more sustainable solutions. They are more likely to arise where decisions are based on unsupported assumptions, one-sided interests or generalised attempts to create uncertainty.
We recognise that Medical Remanufacturing is now also being closely observed by established market participants. This demonstrates that the topic has become firmly established in the market. However, an objective discussion becomes more difficult when broad claims are made without robust supporting evidence.
Questions about regulated reprocessing should be addressed through professional and factual examination, rather than replaced by uncertainty.
For hospitals, the central consideration should be which solution best combines safety, quality, cost-effectiveness and sustainability. Comparing unit prices alone is insufficient, just as the blanket dismissal of reprocessed medical devices is insufficient.
What matters is the quality of the entire process, from acceptance and cleaning through testing and documentation to final product release.
Medical Remanufacturing is not a compromise. It is a regulated approach that brings together patient safety, resource conservation and cost-effectiveness. In doing so, it contributes to a more sustainable and economically resilient healthcare system. Any discussion about it should be based on facts.
